01—Abstract
Summary
Summary of the 10-K filed March 3, 1995. Cited figures are marked; the original filing is the authoritative source.
Important note: the document provided is Schering-Plough Corporation's (NYSE: SGP) Form 10-K for fiscal year 1994, not Merck & Co. (MRK).
The analysis below is based on the Schering-Plough filing. Schering-Plough reported 1994 sales of $4,657.1 milliona, up 7% from $4,341.3 million in 1993. Volume grew 5% and price increases contributed 2%.
Growth was driven mainly by CLARITIN, the nonsedating antihistamine, with worldwide sales of $505 millionb. Net income rose 12% to $922.0 million excluding the 1993 accounting change, and earnings per share were $4.82, up 14% on the same basis. The effective tax rate was 24.0%.
Return on average shareholders' equity was 58.4%, reflecting a small equity base after share repurchases. The main headwinds were Japan and generic competition. Sales of INTRON A in Japan fell to $141 millionc from $307 million after a government-mandated price cut and cost-containment measures.
Generic competition for PROVENTIL and THEO-DUR is expected to weigh on respiratory sales, and PROVENTIL alone generated $396 milliond in 1994. Research and development spending rose 7% to $620.0 million, or 13.3% of sales, and the company says the Puerto Rico tax exemption phase-down will add about 2 percentage points to the effective tax rate starting in 1996. The balance sheet strengthened.
Short-term borrowings fell to $782.3 million from $1,076.0 million, and the ratio of debt to total capital declined to 38% from 44%. The company repurchased 8.6 million shares for $599.4 million and raised the quarterly dividend to $.51 from $.45, bringing the annual dividend to $1.98. Key legal risks include a $63.6 million THEO-DUR product liability judgment under appeal, more than 95 synthetic estrogen (DES-related) suits claiming over $2 billion, and more than 100 pharmacy antitrust actions.
Management considers the probability of material losses beyond amounts accrued to be remote. The company is also still deciding the future of its Wesley-Jessen vision care business, which has received more than $150 million in investment.
02—Key points
Key Highlights
- Net sales of $4,657.1 million in 1994, up 7% from 1993, with volume growth of 5% and price increases of 2%
- Net income of $922.0 million, up 12% excluding the 1993 accounting change; EPS of $4.82 versus $3.75 reported in 1993 (up 14% before one-time items)
- CLARITIN generated worldwide sales of $505 million in 1994, the main driver of growth, with CLARITIN-D launched in the U.S. in November 1994
- INTRON A sales in Japan fell to $141 million from $307 million after a government-mandated price cut, weighing on international anti-infective sales (down 14%)
- Research and development spending of $620.0 million, or 13.3% of sales, with focus on allergy, infectious and cardiovascular disease, oncology, and CNS
- Balance sheet improved: debt-to-capital fell to 38% from 44%, and $599.4 million was used for share buybacks in 1994
- Material risks include a $63.6 million THEO-DUR judgment under appeal, more than 95 DES-related lawsuits claiming over $2 billion, and more than 100 pharmacy antitrust actions
03—Questions
Frequently Asked Questions
Is this filing from Merck & Co. (MRK), as the request states?
No. The filing is Schering-Plough Corporation's 10-K for fiscal year 1994, filed under Commission file number 1-6571. The analysis reflects Schering-Plough's results, not Merck's.
What is driving revenue growth, and what could slow it?
Growth came mainly from CLARITIN and respiratory products, which rose 24% to $1,465 million. The main risks are generic competition for PROVENTIL, expected to hit once a generic albuterol inhaler reaches the market, and THEO-DUR, where generic competition has already reduced sales. Japanese price controls on interferon also cut INTRON A sales sharply.
How strong is the company's financial position?
The company is in strong shape. Operating cash flow was $1,282.5 million, and capital expenditures were $271.6 million. Short-term borrowings fell to $782.3 million, and the company's commercial paper and bond ratings are A-1+/P-1 and AA/Aa3. It also had $866.6 million in unused credit lines. Return on average equity was 58.4%, though this partly reflects a reduced equity base after buybacks.
What is the outlook for the vision care business?
The outlook is uncertain. Schering-Plough entered the disposable contact lens market in 1994 through its Wesley-Jessen subsidiary after investing more than $150 million. Management is evaluating a strategic alliance, licensing, divestiture, or continued operations, and expects to decide on a course of action in 1995.
What are the biggest legal and regulatory exposures?
The main exposures are the DES-related lawsuits (more than 95 suits and over $2 billion in claims), the $63.6 million THEO-DUR judgment (including $57.5 million in punitive damages) under appeal, and more than 100 antitrust cases brought by pharmacies. Management says losses beyond accrued amounts are remote. Health care reform and cost-containment measures in the U.S. and abroad are also ongoing risks.
04—Continue